PharmaShots | Incisive News in 3 Shots

Subscribe Now

aravive

Aravive Reports P-III Trial (AXLerate-OC) Results of Batiraxcept for Platinum-Resistant Ovarian Cancer

Aravive Reports P-III Trial (AXLerate-OC) Results of Batiraxcept for Platinum-Resistant Ovarian Cancer

August 3, 2023

Aravive Reports Updated Results of Batiraxcept in the P-Ib Study for the Treatment of Clear Cell Renal Cell Carcinoma

Aravive Reports Updated Results of Batiraxcept in the P-Ib Study for the Treatment of Clear Cell Renal Cell Carcinoma

March 4, 2022

PharmaShots Interview: Aravive' s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

PharmaShots Interview: Aravive' s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

April 9, 2021

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis

May 1, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us